Mga Batayang Estadistika
| CIK | 1760542 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to HOOKIPA Pharma Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38869 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its |
|
| July 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 29, 2025 As filed with the U.S. Securities and Exchange Commission on July 29, 2025 Registration No. 333-230995 Registration No. 333-237285 Registration No. 333-264587 Registration No. 333-271238 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230995 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STAT |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38869 HOOKIPA Pharma Inc. The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 350 F |
|
| July 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 29, 2025 As filed with the U.S. Securities and Exchange Commission on July 29, 2025 Registration No. 333-230995 Registration No. 333-237285 Registration No. 333-264587 Registration No. 333-271238 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230995 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STAT |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 29, 2025 As filed with the U.S. Securities and Exchange Commission on July 29, 2025 Registration No. 333-230995 Registration No. 333-237285 Registration No. 333-264587 Registration No. 333-271238 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230995 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STAT |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 29, 2025 As filed with the U.S. Securities and Exchange Commission on July 29, 2025 Registration No. 333-230995 Registration No. 333-237285 Registration No. 333-264587 Registration No. 333-271238 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230995 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STAT |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 18, 2025 |
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock Exhibit 99.1 HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock July 18, 2025 at 4:05 PM ET NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) - HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 3, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| June 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| June 16, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| June 16, 2025 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE 14A (Form Type) HOOKIPA Pharma Inc. |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| May 22, 2025 |
AGREEMENT amending the EMPLOYMENT AGREEMENT dated July 22, 2024 Exhibit 10.2 AGREEMENT amending the EMPLOYMENT AGREEMENT dated July 22, 2024 This Agreement (the “Side Letter”) is made between HOOKIPA Biotech GmbH (the “Company”) and Dr. Malte Peters (the “Executive”). Dr. Malte Peters was appointed as Managing Director (Geschäftsführer) of the Company and currently holds this position. The Company and the Executive are parties to an employment agreement dated |
|
| May 22, 2025 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT by and among GILEAD SCIENCES, INC., HOOKIPA PHARMA Inc. and HOOKIPA BIOTECH GmbH Dated as of May 21, 2025 TABLE OF CONTENTS Page Article 1 Definitions 1 Section 1.1 Definitions 1 Article 2 Purchase and sale of transferred assets 2 Section 2.1 Purchase and Sale of the Transferred Assets 2 Section 2.2 Excluded Assets 3 Section 2.3 Assumption of Assumed Liabili |
|
| May 22, 2025 |
Exhibit 10.1 May 21, 2025 Hookipa Biotech GmbH St Marx Vienna BioCenter: Helmut-Qualtinger-Gasse 2 1030 Vienna Austria Attn: Malte Peters, Chief Executive Officer Re: Request to wind-down the HIV Trial Dear Mr. Peters, As you are aware, Gilead Sciences, Inc. (“Gilead”) and Hookipa Biotech GmbH (“Hookipa”) are parties to that certain Amended and Restated Research Collaboration and License Agreement |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38869 HOOKIPA PHARMA INC. ( |
|
| February 28, 2025 |
Termination Agreement between Joern Aldag and HOOKIPA Biotech GmbH dated August 30, 2024 Exhibit 10.14 TERMINATION Agreement entered into by and between HOOKIPA Biotech GmbH (FN 491551w) Helmut-Qualtinger-Gasse 2 1030 Vienna, Austria (the “Company”) and Joern Aldag Date of birth **** Address **** (the “Executive”) as follows: 1. The Company and the Executive are parties to an indefinite employment agreement. The Executive served as the Chief Executive Officer of HOOKIPA Pharma Inc. (a |
|
| February 28, 2025 |
Exhibit 19.1 HOOKIPA PHARMA INC. INSIDER TRADING POLICY This document sets forth the policy of HOOKIPA Pharma Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the appear |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38869 HOOKIPA PHARMA INC. (Exact name of regist |
|
| February 20, 2025 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABU |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| February 14, 2025 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common shares of HOOKIPA Pharma Inc. and further agree that this agreement be included as an exhibit to such filing. Each part |
|
| January 29, 2025 |
VERIFIED PETITION FOR RELIEF UNDER 8 DEL. C. § 205 Exhibit 99.1 IN THE COURT OF CHANCERY FOR THE STATE OF DELAWARE ) IN RE HOOKIPA PHARMA INC. ) C.A. No. ) VERIFIED PETITION FOR RELIEF UNDER 8 DEL. C. § 205 Petitioner HOOKIPA Pharma Inc. (the “Company”) brings this Petition for relief under Section 205 (“Section 205”) of the Delaware General Corporation Law (the “DGCL”): NATURE OF THE ACTION 1. In connection with holding its annual mee |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2025 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINT |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 7, 2025 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINT |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 2, 2025 |
Exhibit 99.2 January 2025 NASDAQ: HOOK HOOKIPA Pharma Next - generation Immunotherapies for the Treatment of Cancer and Other Serious Diseases This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including statements regarding HOOKIPA's expectations regarding the terms, benefits, impacts and timing of the |
|
| January 2, 2025 |
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”) AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER R |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
Exhibit 99.1 HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 14, 2024 |
HOOK / HOOKIPA Pharma Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 hook13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 30, 2024 |
HOOKIPA Pharma Announces Board of Directors Changes Exhibit 99.1 HOOKIPA Pharma Announces Board of Directors Changes NEW YORK and VIENNA, August 30, 2024 (GLOBE NEWSWIRE) - HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O’Neill as Non-Executive Chair of the Company’s Board of Direct |
|
| August 8, 2024 |
Exhibit 99.1 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 ● ASCO 2024 Presentation: Reported best-in-class Phase 2 data for first-line HPV16+ head and ne |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2024 |
Open Market Sale AgreementSM between Jefferies LLC and the Company, dated August 8, 2024 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 8, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: HOOKIPA Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 8, 2024 |
Up to $50,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-266104 PROSPECTUS SUPPLEMENT (To Prospectus dated July 21, 2022) Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sale |
|
| August 2, 2024 |
HOOK / HOOKIPA Pharma Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d877664dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K209 (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| August 2, 2024 |
EX-99.1 2 d877664dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.0001 par value per share, of Hookipa Pharma Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Secu |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 26, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between HOOKIPA Biotech GmbH (the “Company”), and Dr. Malte Peters (the “Executive”) and is made effective with July 22, 2024 and is concluded for an indefinite period (“Term”). WHEREAS, the Company and the Executive are not yet parties to an employment agreement. NOW, THEREFORE, in consideration of the mutual covena |
|
| July 26, 2024 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of July 22, 2024, by and between Mary Theresa Coelho (“Executive”) and HOOKIPA Pharma Inc. (the “Company”). Executive currently serves as a member of the Company’s Board of Directors (the “Board”) and has received certain compensation in connection with such service; The C |
|
| July 26, 2024 |
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 Exhibit 99.1 HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 July 22, 2024 at 8:30 AM EDT · Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer · Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the fu |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 10, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HOOKIPA PHARMA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) HOOKIPA Pharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), |
|
| July 8, 2024 |
HOOK / HOOKIPA Pharma Inc. / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) June 1, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| July 8, 2024 |
EX-99.1 2 d574847dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.0001 par value per share, of Hookipa Pharma Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Secu |
|
| June 18, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HOOKIPA PHARMA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) HOOKIPA Pharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2024 |
Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons. EX-99.1 2 tm2417361d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of HOOKIPA Pharma Inc. This A |
|
| June 14, 2024 |
HOOK / HOOKIPA Pharma Inc. / BAKER BROS. ADVISORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 4, 2024 |
Exhibit 99.1 HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society for Clinical Oncology 2024 Annual Meeting · Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab · In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company |
|
| May 31, 2024 |
HOOK / HOOKIPA Pharma Inc. / EcoR1 Capital, LLC Passive Investment SC 13G 1 hookipa13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) May 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 23, 2024 |
Exhibit 99.1 HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting · HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 · Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity · In a subset of pati |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 9, 2024 |
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights ● Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback ● HB-200 program received Priority Medicines (PRIME) designat |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 9, 2024 |
Exhibit 10.2 AMENDMENT NO. 1 TO THE EMPLOYMENT AGREEMENT This Amendment No. 1 (“Amendment”) is a modification of the Employment Agreement by and between HOOKIPA Biotech GmbH (the “Company”), and Mark Winderlich, PhD MSc (the “Executive”), effective as of June 1, 2024 (“Agreement”). The parties wish to have the Agreement enter into effect two months earlier, so that the new Effective Date shall be |
|
| May 9, 2024 |
Exhibit 10.3 MUTUAL TERMINATION AGREEMENT THIS MUTUAL TERMINATION AGREEMENT is made this March 31, 2024 (the “Effective Date”), by and between Hookipa Biotech GmbH, an Austrian corporation, having its principal place of business at St Marx Vienna BioCenter: Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria ("HOOKIPA"), and Malte Peters, M.D., having its principal place of business at [ADDRESS] (“CON |
|
| May 9, 2024 |
Employment Agreement between Mark Winderlich and HOOKIPA Biotech GmbH, dated November 30, 2023 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between HOOKIPA Biotech GmbH (the “Company”), and Mark Winderlich (the “Executive”) and is made effective as of June 1, 2024 (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein. NOW, THEREFORE |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 HOOKIPA Pharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 25, 2024 |
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab Exhibit 99.1 HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab · Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback · HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 22, 2024 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the registered capital stock of HOOKIPA Pharma Inc. (“us,” “our,” “we” or the “Company”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our amended and restated certificate of incorporation (“Certificate of Incorpor |
|
| March 22, 2024 |
Exhibit 99.1 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights ● Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting o Expect updated Phase 2 data with additional patients in Q2 2024; Company will also provide pivotal t |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38869 HOOKIPA PHARMA INC. (Exact name of regist |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 22, 2024 |
Exhibit 97.1 HOOKIPA PHARMA INC. CLAWBACK POLICY Adopted on September 20, 2023 HOOKIPA Pharma Inc., a Delaware corporation (the “Company”), has adopted a compensation recovery / clawback policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined |
|
| February 14, 2024 |
HOOK / HOOKIPA Pharma Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 hookipa13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2024 |
HOOK / HOOKIPA Pharma Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) HOOKIPA Pharma Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2024 |
HOOK / HOOKIPA Pharma Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242424d17sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* HOOKIPA Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2024 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Hookipa Pharma Inc., |
|
| January 31, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 29, 2024 |
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs Exhibit 99.1 HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs · HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease · HOOKIPA will regain global development rights to HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milestone |
|
| January 2, 2024 |
HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 January 2, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed December 22, 2023 (File No. 333-276220) Ladies and Gentlemen: Pursuant to Rule 461 und |
|
| December 22, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) HOOKIPA Pharma Inc. |
|
| December 22, 2023 |
As filed with the Securities and Exchange Commission on December 22, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 22, 2023 Registration No. |
|
| December 22, 2023 |
HOOK / HOOKIPA Pharma Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP Number) December 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| December 21, 2023 |
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences Exhibit 99.1 HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences · Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share · Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock · Equity investment is to advance the Gilead-partnered HIV therapeutic program t |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 21, 2023 |
Exhibit 10.1 EXECUTION VERSION AMENDED AND RESTATED STOCK PURCHASE AGREEMENT AMENDED AND RESTATED STOCK PURCHASE AGREEMENT (the “A&R Agreement”), dated as of December 20, 2023 (the “Effective Date”) by and between HOOKIPA PHARMA INC., a Delaware corporation (the “Company”), and GILEAD SCIENCES, INC., a Delaware corporation (the “Buyer”). Capitalized terms used herein and not otherwise defined here |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 9, 2023 |
Exhibit 10.1 CONSULTANCY SERVICE AGREEMENT This consultancy service agreement (the “Agreement”) is made among and between: 1. HOOKIPA Biotech GmbH, FN 491551w, Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria (“Company”) and 2. Malte Peters, M.D., *, *, * (“Consultant”), each of them being also designated as a “Party” and together the “Parties”. Preamble WHEREAS A. The Company is active in the biot |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2023 |
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights ● Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 13, 2023 |
HOOKIPA announces executive leadership change Exhibit 99.1 HOOKIPA announces executive leadership change NEW YORK and VIENNA, September 13, 2023 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effe |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 HOOKIPA PHARMA INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 43906K100 |
|
| September 12, 2023 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-I/A (Form Type) HOOKIPA Pharma Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 HOOKIPA PHARMA INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 43906K100 (CUSIP Number of Cla |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 10, 2023 |
Form of Email to Eligible Participants Regarding the Exchange Offer Webinars Exhibit (a)(1)(K) Form of Email to Eligible Participants with Eligible Options Regarding the Exchange Offer Webinars From: HR@hookipapharma. |
|
| August 10, 2023 |
Form of Email to Eligible Participants Confirming Acceptance of Eligible Options. Exhibit (a)(1)(I) FORM OF EMAIL TO ELIGIBLE PARTICIPANTS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS From: HOOKIPA Pharma Inc. |
|
| August 10, 2023 |
Form of Reminder Email to Eligible Holders Regarding the Expiration of the Exchange Offer. Exhibit (a)(1)(H) FORM OF REMINDER EMAIL TO ELIGIBLE HOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: HOOKIPA Pharma Inc. |
|
| August 10, 2023 |
Option Exchange — Election Form. Exhibit (a)(1)(D) OPTION EXCHANGE—ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 10, 2023 |
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights ● HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and neck cancer ● Recruitment ongoing for two Phase 1 clinical trials (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) |
|
| August 10, 2023 |
Form of Email Notice Regarding Rejection of Options for Exchange. Exhibit (a)(1)(J) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: HOOKIPA Pharma Inc. |
|
| August 10, 2023 |
Option Exchange Program Overview Presentation with Transcript. Exhibit (a)(5)(A) Welcome to the Hookipa information event on our stock option exchange offer 1 Stock options are issued to provide an incentive to our employees in addition to the fixed and variable cash compensation; Unfortunately, the market situation for biotech stocks, and the Hookipa stock in particular has declined substantially over the past two years, which has caused frustration for some options holders; Therefore, our BoD has decided to give employees the opportunity to exchange some old options with exercise prices of $6. |
|
| August 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-I (Form Type) HOOKIPA Pharma Inc. |
|
| August 10, 2023 |
Form of Email Confirming Receipt of Option Exchange Election Form. Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF OPTION EXCHANGE ELECTION FORM From: HOOKIPA Pharma Inc. |
|
| August 10, 2023 |
Form of Announcement Email to Eligible Participants. Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE PARTICIPANTS From: Legal@hoopikapharma. |
|
| August 10, 2023 |
Option Exchange — Notice of Withdrawal of Election Form. Exhibit (a)(1)(E) OPTION EXCHANGE—NOTICE OF WITHDRAWAL OF ELECTION FORM THE EXCHANGE OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P. |
|
| August 10, 2023 |
Form of Announcement Email to All Employees. Exhibit (a)(1)(C) Form of Announcement Email to All Employees From: Joern Aldag Subject: Hookipa Offer to Exchange Eligible Options for New Options To: All Employees Date: August 10, 2023 Dear all, I am pleased to share with you that our Board of Directors has approved an Offer to Exchange Eligible Options for New Options (“Exchange Offer”) that will begin today, August 10, 2023. |
|
| August 10, 2023 |
Offer to Exchange Eligible Options for New Options, dated August 10, 2023. TABLE OF CONTENTS Exhibit (a)(1)(A) HOOKIPA PHARMA INC. 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 NEW YORK, NEW YORK 10118 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS August 10, 2023 HOOKIPA PHARMA INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS This offer and withdrawal rights will expire at 11:59 p.m., Eastern Daylight Time, on September 7, 2023, unle |
|
| August 10, 2023 |
Form of Email Confirming Receipt of Notice of Withdrawal of Election. Exhibit (a)(1)(G) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION From: HOOKIPA Pharma Inc. |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2023 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File |
|
| June 20, 2023 |
HOOK / Hookipa Pharma Inc / Knoll Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Hookipa Pharma Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 43906K100 (CUSIP Number) May 31 |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2023 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 2, 2023 |
22,900,768 Shares of Common Stock and 15,268 Shares of Series A-2 Convertible Preferred Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-266104 PROSPECTUS SUPPLEMENT (to Prospectus dated July 21, 2022) 22,900,768 Shares of Common Stock and 15,268 Shares of Series A-2 Convertible Preferred Stock We are offering 22,900,768 shares of our common stock, par value $0.0001 per share. Our common stock is listed on The Nasdaq Global Select Market under the symbol “HOO |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 2, 2023 |
Exhibit 99.1 HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, May 31, 2023 – HOOKIPA Pharma Inc. (Nasdaq: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22, |
|
| June 2, 2023 |
Exhibit 1.1 HOOKIPA PHARMA INC. (a Delaware corporation) 22,900,768 Shares of Common Stock 15,268 Shares of Series A-2 Convertible Preferred Stock UNDERWRITING AGREEMENT Dated: May 31, 2023 HOOKIPA PHARMA INC. (a Delaware corporation) 22,900,768 Shares of Common Stock 15,268 Shares of Series A-2 Convertible Preferred Stock UNDERWRITING AGREEMENT SVB Securities LLC RBC Capital Markets, LLC as Repre |
|
| June 2, 2023 |
Exhibit 3.1 HOOKIPA PHARMA INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW HOOKIPA PHARMA INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in |
|
| May 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 31, 2023 |
Exhibit 99.1 HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers · HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients with recurrent/metastatic head and neck cancer · HOOKIPA is preparing to start a pivotal trial of HB-200 in combination |
|
| May 11, 2023 |
Employment Agreement between Christine Baker and the Registrant, dated August 1, 2019 Exhibit 10.2 MANAGEMENT EMPLOYMENT AGREEMENT This Management Employment Agreement (“Agreement”) is made between HOOKIPA Pharma Inc., a Delaware corporation (the “Company”), and Christine Baker (the “Executive”) and is made effective as of 1st August 2019 (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 11, 2023 |
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights ● HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 ● Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) ● HB-700 for KRAS-mutated cance |
|
| May 11, 2023 |
Exhibit 10.1 HOOKIPA PHARMA INC. 2019 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the HOOKIPA Pharma Inc. 2019 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of HOOKIPA Pharma Inc. (the “Company”) and its Affiliates upon w |
|
| April 13, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) HOOKIPA Pharma Inc. |
|
| April 13, 2023 |
As filed with the Securities and Exchange Commission on April 13, 2023 As filed with the Securities and Exchange Commission on April 13, 2023 Registration No. |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 13, 2023 |
Exhibit 10.1 HOOKIPA PHARMA INC. 2023 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the HOOKIPA Pharma Inc. 2023 Inducement Plan (the “Plan”). The purpose of the Plan is to encourage and enable HOOKIPA Pharma Inc. (the “Company”) to grant equity awards to induce highly qualified prospective officers and employees who are not currently employed by |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2023 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File |
|
| March 15, 2023 |
Exhibit 10.29 AMENDMENT NO. 2 TO LICENSE AGREEMENT This amendment (the “Amendment No. 2”) is a modification of the License Agreement by and between University of Basel, having its principal place of business at Petersgraben 35, CH-4001 Basel, Switzerland (“UNIVERSITY”), and Hookipa Biotech GmbH, having its principal place of business at Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria (“LICENSEE”), |
|
| March 15, 2023 |
Exhibit 10.28 AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment (“Amendment”) is a modification of the License Agreement by and between University of Basel, having its principal offices located at Petersgraben 35, 4001 Basel, Switzerland (“UNIBAS”) and Hookipa Biotech GmbH, having its principal offices located at Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria (“Hookipa”), made effective on Octo |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38869 HOOKIPA PHARMA INC. (Exact name of regist |
|
| March 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 15, 2023 |
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook Exhibit 99.1 HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook ● Data from Phase 2 study of HB-200 in combination with pembrolizumab in head and neck cancers expected in 2Q 2023 ● Phase 1 HB-300 trial in metastatic castration-resistant prostate cancer open for enrollment ● KRAS program (HB-700) achieved its first milestone payment in the Roche collaborat |
|
| March 13, 2023 |
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors Exhibit 99.1 HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors New York, US and Vienna, Austria, March 13, 2023 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective Apr |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2023 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2023 |
EX-99.1 2 tm234999d21ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of HOOKIPA Pharma Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. ADVISORS |
|
| February 14, 2023 |
EX-99.1 2 tm236041d20ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 |
|
| February 14, 2023 |
HOOK / Hookipa Pharma Inc / GILEAD SCIENCES INC Passive Investment SC 13G/A 1 hookipa13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP Number) March 24, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 14, 2023 |
HOOK / Hookipa Pharma Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
HOOK / Hookipa Pharma Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) HOOKIPA Pharma Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 14, 2023 |
HOOK / Hookipa Pharma Inc / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm234999d21sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* HOOKIPA Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2023 |
HOOK / Hookipa Pharma Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2023 |
HOOK / Hookipa Pharma Inc / SOFINNOVA CAPITAL VI FCPR - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 13, 2023 |
Exhibit 99.1 Page 1 of 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of Hookipa Pharma Inc. and further agree that this agreement be included as an exhibit to such filing |
|
| February 9, 2023 |
HOOK / Hookipa Pharma Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 HOOKIPA PHARMA INC COMMON STOCK Cusip #43906K100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #43906K100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,895,600 Item 6: 0 Item 7: 4,895,600 Item 8: 0 Item 9: |
|
| January 20, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 17, 2023 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 15, 2022 |
Exhibit 99.1 HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors December 15, 2022 NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ?HOOKIPA?), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Ka |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2022 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2022 |
HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update Exhibit 99.1 HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update ● Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidate ● Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer accepted by |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 20, 2022 |
Exhibit 10.1 Certain information has been excluded from this agreement (indicated by “[***]”) HOOKIPA PHARMA INC. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. Research Collaboration and License Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F. Hoffmann-La Roche Ltd |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 20, 2022 |
Exhibit 99.1 HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers ● Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapy ● HOOKIPA to receive $25 million in upfront cash as well as potential future success-based milestone payments up to |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 OR ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) ? ? ? ? ? ? Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) |
|
| August 11, 2022 |
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates Exhibit 99.1 HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates ● HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underway ● US Food and Drug Administration accepted HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer |
|
| July 19, 2022 |
HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 July 19, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed July 12, 2022 (File No. 333-266104) Ladies and Gentlemen: Pursuant to Rule 461 under the |
|
| July 13, 2022 |
HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 HOOKIPA Pharma Inc. 350 Fifth Avenue, 72nd Floor, Suite 7240 New York, New York 10118 July 13, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed July 11, 2022 (File No. 333-266084) Ladies and Gentlemen: Pursuant to Rule 461 under the |
|
| July 12, 2022 |
July 12, 2022 By EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Attention: Ms. Ada Sarmento, Division of Corporation Finance Re: HOOKIPA Pharma, Inc. Registration Statement on Form S-3 (File No. 333-266084) Dear Ms. Sarmento: Reference is made to the Registration Statement on Form S-3 (File No. 333-266084) filed by HOOKIPA Pharma, Inc. on July 11, 2022 (the |
|
| July 12, 2022 |
Exhibit 4.2 HOOKIPA PHARMA INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Cer |
|
| July 12, 2022 |
As filed with the Securities and Exchange Commission on July 12, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 12, 2022 Registration No. |
|
| July 12, 2022 |
Sales Agreement, dated as of July 12, 2022, by and between the Company and SVB Securities LLC Exhibit 1.2 HOOKIPA PHARMA INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT July 12, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: HOOKIPA Pharma Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as follows: 1. Issuance and Sale of S |
|
| July 12, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) HOOKIPA Pharma Inc. |
|
| July 12, 2022 |
Form of indenture for senior debt securities and the related form of senior debt security Exhibit 4.3 HOOKIPA PHARMA INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certifica |
|
| July 11, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) HOOKIPA Pharma Inc. |
|
| July 11, 2022 |
As filed with the Securities and Exchange Commission on July 11, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 11, 2022 Registration No. |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2022 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File |
|
| July 1, 2022 |
Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?HOOKIPA PHARMA INC.?, FILED IN THIS OFFICE ON THE THIRTIETH DAY OF JUNE, A.D. 2022, AT 12:27 O?CLOCK P.M. 6317212 8100 SR# 20222875812 Authentication: 203813208 Date: 06-30-22 You may verify thi |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 22, 2022 |
Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 17, 2022, by and among HOOKIPA Pharma Inc., a Delaware corporation (the ?Company?), and the Gilead Sciences, Inc. (the ?Purchaser?). This Agreement is made pursuant to the Stock Purchase Agreement, dated as of February 15, 2022 between the Company and the Purchaser ( |
|
| June 22, 2022 |
HOOKIPA Announces Executive Leadership Changes Exhibit 99.1 HOOKIPA Announces Executive Leadership Changes New York, US and Vienna, Austria, June 21, 2022 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ?HOOKIPA?), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs. All new appointments are eff |
|
| June 6, 2022 |
Exhibit 99.1 HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO ? Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy ? Phase 2 to proceed with alternating 2-vector therapy in combination with pembrolizu |
|
| June 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) ? ? ? ? ? ? Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (C |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant?x Filed by a party other than the Registrant?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 16, 2022 |
DEF 14A 1 tm223578-2def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 OR ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| May 16, 2022 |
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights Exhibit 99.1 ? ? ? HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights ? ? HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizumab in second half of 2022 ? Q1 capital raise and Gilead collaboration funding generated a strong cash position of $142 million New York, US and Vienna, Austria, May 16, 2022 - HOOKIPA Pharma Inc |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2022 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 2, 2022 |
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer Exhibit 99.1 HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer New York, US and Vienna, Austria, May 2, 2022 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ?HOOKIPA?), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately. Christine jo |
|
| May 2, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) ? Filed by the Registrant?? Filed by a party other than the Registrant?? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| May 2, 2022 |
Auditor Name PwC Wirtschaftspr?fung GmbH Auditor Location Vienna, Austria UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 29, 2022 |
As filed with the Securities and Exchange Commission on April 29, 2022 As filed with the Securities and Exchange Commission on April 29, 2022 Registration No. |
|
| April 29, 2022 |
EX-FILING FEES 4 tm2213961d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) HOOKIPA Pharma Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be registered (1) Proposed maximum offering price per share Maximum Aggregate Offering Price Fee |
|
| April 20, 2022 |
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors Exhibit 99.1 HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors New York, US and Vienna, Austria, April 20, 2022 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ?HOOKIPA?), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately. ?We?re pleased to |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 15, 2022 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-38869 81-5395687 (State or other jurisdiction of incorporation) (Commission File |
|
| April 8, 2022 |
HOOK / Hookipa Pharma Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Hookipa Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) March 2, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| March 24, 2022 |
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook Exhibit 99.1 ? ? ? HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook ? Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients ? HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pembrolizu |
|
| March 24, 2022 |
Exhibit 3.1 ? AMENDED AND RESTATED ? CERTIFICATE OF INCORPORATION ? OF ? HOOKIPA PHARMA INC. ? HOOKIPA Pharma Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: ? 1. The name of the Corporation is HOOKIPA Pharma Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of th |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 24, 2022 |
Exhibit 10.15 EMPLOYMENT AGREEMENT ? This Employment Agreement (?Agreement?) is made between HOOKIPA Biotech GmbH (the ?Company?), and Klaus Orlinger (the ?Executive?) and is made effective as of January 1, 2022 (the ?Effective Date?). ? WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein. ? WHERA |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) ? ? ? ? ? ? Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) |
|
| March 24, 2022 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 ? Exhibit 4.3 ? DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the registered capital stock of HOOKIPA Pharma Inc. (?us,? ?our,? ?we? or the ?Company?) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our amended and restated certificate of incorporation (?Certificate of Inco |
|
| March 4, 2022 |
HOOK / Hookipa Pharma Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 3, 2022 |
Exhibit 3.1 HOOKIPA PHARMA INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW HOOKIPA PHARMA INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does hereby certify that, in |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 3, 2022 |
21,700,000 Shares of Common Stock and 15,800 Shares of Series A-1 Convertible Preferred Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-238311? FINAL PROSPECTUS SUPPLEMENT (to Prospectus dated May 27, 2020) 21,700,000 Shares of Common Stock and 15,800 Shares of Series A-1 Convertible Preferred Stock ? We are offering 21,700,000 shares of our common stock, par value $0.0001 per share. Our common stock is listed on The Nasdaq Global Select Market under the sy |
|
| March 3, 2022 |
Exhibit 99.1 HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, March 2, 2022 ? HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 21,700,000 sh |
|
| March 3, 2022 |
Exhibit 1.1 HOOKIPA PHARMA INC. (a Delaware corporation) 21,700,000 Shares of Common Stock 15,800 Shares of Series A-1 Convertible Preferred Stock UNDERWRITING AGREEMENT Dated: March 1, 2022 HOOKIPA PHARMA INC. (a Delaware corporation) 21,700,000 Shares of Common Stock 15,800 Shares of Series A-1 Convertible Preferred Stock UNDERWRITING AGREEMENT SVB Securities LLC RBC Capital Markets, LLC as Repr |
|
| March 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 1, 2022 |
Exhibit 10.1 AMENDED AND RESTATED RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between gilead sciences, Inc. and hookipa biotech gmbH TABLE OF CONTENTS 1. DEFINITIONS AND INTERPRETATION 1 2. PROGRAMS 17 3. LICENSES; EXCLUSIVITY 21 4. GOVERNANCE 23 5. TECHNOLOGY TRANSFERS 28 6. DEVELOPMENT AND REGULATORY MATTERS 29 7. MANUFACTURING 31 8. COMMERCIALIZATION 32 9. FINANCIAL PROVISIONS 32 10. RE |
|
| March 1, 2022 |
Exhibit 99.1 HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, March 1, 2022 ? HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shares of its |
|
| March 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorpora |
|
| March 1, 2022 |
SUBJECT TO COMPLETION, DATED MARCH 1, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| February 17, 2022 |
HOOK / Hookipa Pharma Inc / GILEAD SCIENCES INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 3)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP Number) February 15, 2022 |
|
| February 15, 2022 |
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV Exhibit 99.1 HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV ? HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter ? Financial terms include $15 million initiation fee and $35 million equity commitment New York City, US and Vienn |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 15, 2022 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT STOCK PURCHASE AGREEMENT (the ?Agreement?), dated as of February 15, 2022 (the ?Effective Date?) by and between HOOKIPA PHARMA INC., a Delaware corporation (the ?Company?), and GILEAD SCIENCES, INC., a Delaware corporation (the ?Buyer?). Capitalized terms used herein and not otherwise defined herein are defined in Section 11 hereof. WHEREAS: Simultaneously upo |
|
| February 14, 2022 |
HOOK / Hookipa Pharma Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) HOOKIPA Pharma Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 43906K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of HOOKIPA Pharma Inc., |
|
| February 11, 2022 |
HOOK / Hookipa Pharma Inc / Forbion Capital Fund II Cooperatief U.A. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HOOKIPA Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K100 (CUSIP Number) 31 DECEMBER 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) ? ? ? ? ? ? Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporatio |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 OR ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| November 10, 2021 |
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights Exhibit 99.1 ? ? ? HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights ? Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1st- and 2nd-line HNSCC patients ? Based on recent strong data updates, HOOKIPA advancing HB-201 to Phase 2, prioritizing immuno-oncology pipeline across numerous cancer |
|
| November 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2021 |
Exhibit 99.1 HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform ? Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st- and 2nd-line head and neck cancer ? Interim Phase 1 HB-200 data continue to show high levels of tumor-specif |
|
| August 30, 2021 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. The reported securities are beneficially owned by Takeda Ventures, Inc., a direct wholly-owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc., which, in turn, is a direct subsidiary of Takeda Pharmaceuticals International AG and Takeda Pharmaceutical Company Limited. Takeda |
|
| August 30, 2021 |
Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of HOOKIPA Pharma Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under |
|
| August 30, 2021 |
HOOK / Hookipa Pharma Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP Number) July 22, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) ? ? ? ? ? ? Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 OR ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| August 12, 2021 |
HOOKIPA Pharma Reports Second Quarter 2021 Financial Results and Recent Highlights Exhibit 99.1 ? ? ? HOOKIPA Pharma Reports Second Quarter 2021 Financial Results and Recent Highlights ? ? Phase 1 HB-200 data recognized at premier oncology meetings, highlighting potential of novel arenaviral platform to deliver a new class of immunotherapeutics ? HOOKIPA on track to report comprehensive data from oncology and infectious disease programs in the second half of 2021 New York, Unite |
|
| June 7, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 HOOKIPA PHARMA INC. (Exact name of Registrant as Specified in Its Charter) ? Delaware 001-38869 81-5395687 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| May 12, 2021 |
HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights Exhibit 99.1 ? ? ? HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights ? ? Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202; clinical results consistent with those observed in pre-clinical studies ? HOOKIPA on track to report additional HB-201 and HB-202 clini |
